Abstract: A technique capable of providing a user with information obtained by OCT imaging in a useful way, particularly for assisting in assessment of an embryo effectively. The image processing method includes acquiring original signal data indicating an intensity distribution of signal light from each position in three-dimensional space including a cultured embryo obtained by optical coherence tomography imaging, generating spherical coordinate data based on the original signal data, the spherical coordinate data indicating a relationship between each position in the three-dimensional space represented using spherical coordinates having an origin set inside the embryo and the intensity of the signal light from the position, and outputting the intensity distribution of the signal light as a two-dimensional map based on the spherical coordinate data using two deflection angles of the spherical coordinates as coordinate axes.

Abstract: [Problem] To provide a composition and a cell sheet which are highly effective for inhibiting fibrosis, or cells having fibrosis-inhibiting activity, which are useful in regenerative medicine. [Solution] A medium containing IC-2 or a related compound is inoculated with mesenchymal stem cells or bone marrow mononuclear cells, and the cells are cultured for a prescribed period of time while the IC-2 or related compound is maintained at a constant concentration, thereby allowing a composition and a cell sheet which are highly effective for inhibiting fibrosis, or cultured cells having fibrosis-inhibiting activity, to be obtained.

Abstract: An object of the present invention is to provide a method for producing a reversibly immortalized cell which can allow a cell into which an immortalizing gene is introduced to proliferate over a long period without damaging the chromosome of the cell, and is capable of removing the immortalizing gene, and to provide a method for obtaining a large amount of a reversibly immortalized cell that can be cloned and has stable quality. The present invention provides a method for producing a reversibly immortalized cell, comprising the steps of: introducing a chromosomally non-integrated RNA virus vector loaded with one or two or more immortalizing gene(s), selected from the group consisting of Bmi-1 gene, TERT gene, and SV40T gene, into a mammalian cell so that the immortalizing gene is expressed in the cell; and culturing the obtained cell for proliferation.

Abstract: In this application, the provided are: a Down syndrome rat model characterized in that a rat gene homologous to at least one gene present on a human chromosome 21 or fragment thereof is a trisomy and is transmittable to progeny; or a Down syndrome rat model characterized in that it comprises a human chromosome 21 or fragment thereof, or an exogenous rat chromosome or fragment thereof on which a rat gene homologous to the human chromosome 21 or fragment thereof is present, wherein at least one gene on the human chromosome 21 or fragment thereof or on the exogenous rat chromosome or fragment thereof is added to endogenous rat genes homologous to the at least gene so as to become a trisomy and to be transmittable to progeny: and a method for producing the Down syndrome rat model.

Abstract: The present invention provides a vaccinia virus which specifically grows in cancer cells and damages cancer cells and use of the virus for cancer treatment. The oncolytic vaccinia is deficient in a region consisting of 7000 to 9000 nucleotides in the genome sequence of a vaccinia virus and does not grow in normal cells, but grows specifically in cancer cells and damages cancer cells specifically.

Abstract: A vaccinia virus into which a therapeutic gene has been introduced as an exogenous gene and a therapeutic composition containing the same. The vaccinia virus contains at least one immune regulating gene as an exogenous gene.

Abstract: The present invention provides: a complex comprising a genome editing enzyme and a cell membrane-permeable peptide(CPP), wherein the CPP is fused to the genome editing enzyme; a complex comprising a genome editing enzyme, a target gene-specific nucleic acid, and a CPP, wherein the CPP is fused to the genome editing enzyme and/or the a target gene-specific nucleic acid; the complex comprising a polycationic moiety fused to the CPP, wherein the polycation moiety is statically bound to the target gene-specific nucleic acid; a genome editing method using the complex; and a kit for genome-editing, the kit including these complexes.

Abstract: This invention provides a method for producing a glycan with improved yield ratio of streocontrolled glycan. Additionally it provides the building blocks used as the sugar donor and as the sugar acceptor to implement a method for producing the glycan. It also provides a novel compound. It subjects the specific building block A of this invention to electrolytic oxidation in an aprotic organic solvent that contains an electrolyte; and subjects the specific building block B of this invention to glycosylation with the electrolytically oxidized building block A in the method for producing a glycan based on the liquid phase process.

Abstract: Provided are the following: an MWW type zeolite which has many Brønsted acid sites when in the form of a proton type and which is highly suitable as a cracking catalyst for cumene; a method for producing same; and an application of same. The present invention provides an MWW type zeolite in which the ratio (B/A) of the peak intensity (B) attributable to tetracoordinate aluminum relative to the peak intensity (A) attributable to hexacoordinate aluminum is 2 or more in 27Al MAS NMR, when measured as an ammonium type. The present invention also provides a method for producing an MWW type zeolite, the method having a step for carrying out a hydrothermal synthesis reaction in the presence of: a seed crystal of an MWW type zeolite containing no organic structure-directing agent; and a reaction mixture containing a silica source, an alumina source, an alkali source, an organic structure-directing agent, and water. The reaction mixture satisfies the following molar ratio: X/SiO2<0.

Abstract: This invention provides a vaccinia virus that induces cell fusion between infected cells and a method for producing the same. Such vaccinia virus is deprived of the K2L gene or the HA gene or functions of the K2L gene and the HA gene and is mutated to induce cell fusion between infected cells and induce cell death.

Abstract: Provided are the following: an MWW type zeolite which has many Brønsted acid sites when in the form of a proton type and which is highly suitable as a cracking catalyst for cumene; a method for producing same; and an application of same. The present invention provides an MWW type zeolite in which the ratio (B/A) of the peak intensity (B) attributable to tetracoordinate aluminum relative to the peak intensity (A) attributable to hexacoordinate aluminum is 2 or more in 27Al MAS NMR, when measured as an ammonium type. The present invention also provides a method for producing an MWW type zeolite, the method having a step for carrying out a hydrothermal synthesis reaction in the presence of: a seed crystal of an MWW type zeolite containing no organic structure-directing agent; and a reaction mixture containing a silica source, an alumina source, an alkali source, an organic structure-directing agent, and water. The reaction mixture satisfies the following molar ratio: X/SiO2<0.

Abstract: A conductive bridge memory device includes a memory cell including a first metal layer; a second metal layer; a first insulator layer having a first surface facing the first metal layer and a second surface facing the second metal layer and being a surface opposite to the first surface, and having a through hole penetrating between the first surface and the second surface; and a liquid layer being formed of liquid containing a liquid electrolyte impregnated in the through hole.

Abstract: It is provided a technique capable of noninvasively and quantitatively evaluating the state of cultured three-dimensional cell-based structure. A method of evaluating a three-dimensional cell-based structure according to the present invention comprises: performing tomography of the cultured three-dimensional cell-based structure (step S103); generating stereoscopic data indicating the three-dimensional shape of the three-dimensional cell-based structure based on image data acquired by the tomography (step S104); and counting the number of structures isolated from each other in the three-dimensional cell-based structure based on the stereoscopic data (step S105).

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: The present invention provides a therapeutic agent or a prophylactic agent of dementia containing xanthine oxidase inhibitor such as a compound represented in formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: Provided is a silyl ether-containing sulfonate salt that contains an anion represented by formula (1) and a cation. (In the formula, R1 to R4 are each independently a C1-4 alkyl group. m is an integer from 1 to 3. n is an integer from 2 to 8.

Abstract: A novel therapeutic drug for malignant tumors, cancer stem cells, or fibrosis is obtained. A therapeutic drug for malignant tumors or cancer stem cells is used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof. Alternatively, a therapeutic drug for fibrosis can be used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof.

Abstract: A high-performance CB-RAM having a low operating voltage and a high switching endurance even when alumina is used for the insulator layer; wherein, an electrolyte layer impregnated in a pore of an insulator layer is configured to include a mixed ionic liquid in which is mixed a solvate ionic liquid, and a low-viscous ionic liquid being an ionic liquid having a viscosity coefficient smaller than that of the solvate ionic liquid.

Abstract: The purpose of the present invention is to provide a metal-substituted beta zeolite that exhibits a more excellent catalytic performance than conventional one, and a method for producing the same. The present invention provides a metal-substituted beta zeolite by subjecting an alkali metal-form beta zeolite produced without using an organic structure-directing agent to ion exchange with ammonium ion and then, using a filter cake procedure, to ion exchange with copper ion or iron(II) ion. The present invention also provides a metal-substituted beta zeolite which has been ion exchanged with copper ion or iron(II) ion and in which the amount of Lewis acid sites is greater than the amount of Bronsted acid sites when the amount of Bronsted acid sites and the amount of Lewis acid sites are measured by ammonia infrared-mass spectroscopy temperature-programmed desorption on the as-produced state.

Abstract: The present invention provides a therapeutic agent or a prophylactic agent of dementia containing xanthine oxidase inhibitor such as a compound represented in formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt thereof as an active ingredient.